Ptc Therapeutics (PTCT) EBIAT (2016 - 2025)
Historic EBIAT for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $15.9 million.
- Ptc Therapeutics' EBIAT rose 11490.43% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $751.7 million, marking a year-over-year increase of 26586.97%. This contributed to the annual value of -$363.3 million for FY2024, which is 4202.16% up from last year.
- According to the latest figures from Q3 2025, Ptc Therapeutics' EBIAT is $15.9 million, which was up 11490.43% from -$64.8 million recorded in Q2 2025.
- Ptc Therapeutics' EBIAT's 5-year high stood at $866.6 million during Q1 2025, with a 5-year trough of -$198.9 million in Q2 2023.
- Moreover, its 5-year median value for EBIAT was -$126.7 million (2022), whereas its average is -$66.1 million.
- Its EBIAT has fluctuated over the past 5 years, first tumbled by 9173.51% in 2021, then soared by 104627.63% in 2025.
- Over the past 5 years, Ptc Therapeutics' EBIAT (Quarter) stood at -$143.3 million in 2021, then dropped by 19.28% to -$170.9 million in 2022, then rose by 8.83% to -$155.8 million in 2023, then surged by 57.71% to -$65.9 million in 2024, then skyrocketed by 124.13% to $15.9 million in 2025.
- Its last three reported values are $15.9 million in Q3 2025, -$64.8 million for Q2 2025, and $866.6 million during Q1 2025.